The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients differentiated thyroid carcinoma before and during thyroxine withdrawal

European Journal of Endocrinology

Volumn 153, Issue 2, 2005, Pages 223-230

  Botella Carretero, José I ^a   Prados, Aranzazu ^a   Manzano, Luis ^a   Montero, María T ^a   Escribano, Luis ^a   Sancho, José ^a   Escobar Morreale, Héctor F ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR; LIOTHYRONINE; THYROID HORMONE; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTHYROIDISM; IMMUNOMODULATION; IMMUNOREGULATION; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID FUNCTION; THYROID HORMONE BLOOD LEVEL; THYROID HORMONE RELEASE;

ADULT; ANTITHYROID AGENTS; AUTOIMMUNITY; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOKINES; FEMALE; HUMANS; HYPERTHYROIDISM; IMMUNE SYSTEM; KILLER CELLS, NATURAL; MIDDLE AGED; PROSPECTIVE STUDIES; THYROID GLAND; THYROID NEOPLASMS; THYROXINE; TRIIODOTHYRONINE;

EID: 23844552184     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01951     Document Type: Article

References (39)

1. Dorshkind K & Horseman ND. The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocrine Reviews 2000 21 292-312.
2. Fabris N, Mocchegiani & Provinciali M. Pituitary-thyroid axis and immune system: a reciprocal neuroendocrine-immune interaction. Hormone Research 1995 43 29-38.
3. Fabris N. Immunodepression in thyroid-deprived animals. Clinical and Experimental Immunology 1973 15 601-611.
4. Weetman AP & McGregor AM. Autoimmune thyroid disease, further developments in our understanding. Endocrine Reviews 1994 15 778-803.
5. Volpe R. Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signalling: a review. Thyroid 1994 4 217-223.
6. Brostoff J & Hall T. Immunity against tumours. In Immunology, Roitt IM, Brostoff J & Male DK eds. edn 2, ch. 19, pp 5-11. London: Gower Medical Publishing, 1991.
7. Papamichail M, Perez SA, Gritzapis AD & Baxevanis CN. Natural killer lymphocytes: biology, development and function. Cancer Immunology and Immunotherapy 2004 53 176-186.
8. Abbas AK, Lichtman AH & Pober JS. Cellular and Molecular Immunology, edn 4. WB Saunders Company, 2000.
9. Janeway CAJ, Travers P, Walport M & Shlomchik MJ. Immunobiology: the Immune System in Health and Disease, edn 5. New York: Garland Publishing, Taylor & Francis Books Inc., 2001.
10. Dinarello CA. IL-18: a Th1-inducing, proinflammatory cytokine and new member of the IL-1 family. Journal of Allergy and Clinical Immunology 1999 103 11-24.
11. Germann T & Rude E. Interleukin-12. International Archives of Allergy and Immunology 1995 108 103-112.
12. De Groot L, Manowitz N, Chait L, & Mayor G. Differential end organ responsiveness to suboptimal thyroid hormone concentrations as assessed by short-term withdrawal of levothyroxine sodium in athyreotic patients. Proceedings of the 70th Annual Meeting of the American Thyroid Association, Colorado Springs, CO, USA 1997 S-88.
13. Botella-Carretero JI, Galán JM, Caballero C, Sancho J & Escobar-Morreale HF. Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocrine-Related Cancer 2003 10 601-611.
14. Botella-Carretero JI, Gómez-Bueno M, Barrios V, Caballero C, García-Robles R, Sancho J & Escobar-Morreale HF. Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are asssociated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocrine-Related Cancer 2004 11 345-356.
15. Suffredini AF, Fantuzzi G, Badolato R, Oppenheim JJ & O'Grady NP. New insights into the biology of the acute phase response. Journal of Clinical Immunology 1999 19 203-214.
16. Lebel-Binay S, Berger A, Zinzindohoue F, Cugnene PH, Thiounn N, Fridman WH & Pages F. Interleukin-18: biological properties and clinical implications. European Cytokine Network 2000 11 15-25.
17. Xia D, Li F & Xiang J. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity. Cancer Biotherapy and Radiopharmaceuticals 2004 19 322-330.
18. Chung SW, Cohen EP & Kim TS. Generation of tumor-specific cytotoxic T lymphocytes and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide. Vaccine 2004 22 2547-2557.
19. Zhang B, Wu KF, Lin YM, Ma XT, Rao Q, Zheng GG, Cao ZY, Li G & Song YH. Gene transfer of pro-IL-18 and IL-1beta converting enzyme cDNA induces potent antitumor effects in L1210 cells. Leukemia 2004 18 817-825.
20. Mahoney MX, Currier NL & Miller SC. Natural killer cell levels in older adult mice are gender-dependent: thyroxine is a gender-independent natural killer cell stimulant. Natural Immunity 1998 16 165-174.
21. Provinciali M & Fabris N. Modulation of lymphoid cell sensitivity to interferon by thyroid hormones. Journal of Endocrinological Investigation 1990 13 187-191.
22. Provinciali M, Muzzioli M, Di Stefano G & Fabris N. Recovery of spleen cell natural killer activity by thyroid hormone treatment in old mice. Natural Immunity and Cell Growth Regulation 1991 10 226-236.
23. Provinciali M, Muzzioli M & Fabris N. Thyroxine-dependent modulation of natural killer activity. Journal of Experimental Pathology 1987 3 617-622.
24. Papic M, Stein-Streilein J, Zakarija M, McKenzie JM, Guffee J & Fletcher MA. Suppression of peripheral blood natural killer cell activity by excess thyroid hormone. Journal of Clinical Investigation 1987 73 404-408.
25. Farid NR, Munro RE, Row VV & Volpe R. Peripheral thymus-dependent (T) lymphocytes in Graves' disease and Hashimoto's thyroiditis. New England Journal of Medicine 1973 288 1313-1317.
26. Corrales JI, Orfao A, Lopez A, Mories MT, Miralles JM & Ciudad J. Analysis of IL-2 and IL-6 binding to peripheral blood lymphocytes in Graves' disease: relationship with disease activity. Cytometry 1997 30 118-123.
27. Escobar-Morreale HF, Serrano-Cotarredona J, Villar LM, Garcia-Robles R, Gonzalez-Porque P, Sancho JM & Varela C. Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin-2 receptor, and beta-microglobulin in patients with Graves' disease. Thyroid 1996 6 29-36.
28. Miyauchi S, Matsuura B & Onji M. Increased levels of serum interleukin-18 in Graves' disease. Thyroid 2000 10 815-819.
29. Siddiqi A, Monson JP, Wood DF, Besser GM & Burrin JM. Serum cytokines in thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism 1999 84 435-439.
30. Tamaru M, Matsuura B & Onji M. Increased levels of serum interleukin-12 in Graves' disease. European Journal of Endocrinology 1999 141 111-116.
31. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JP & Roti E. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. European Journal of Endocrinology 2000 143 197-202.
32. Ahmad L, Parkes A, Lazarus J, Bartanela L, Martino E, Diamond E & Stagnaro-Green A. Interleukin-6 levels are not increased in women with postpartum thyroid dysfunction. Thyroid 1998 8 371-375.
33. Bossowski A & Urban M. Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter. Journal of Pediatric Endocrinology and Metabolism 2001 14 741-747.
34. Chandratilleke D, Hala K & Marsh JA. Effects of in vivo thyroid hormone treatment on the expression of interleukin-2 receptors on avian splenocytes. International Journal of Immunopharmacology 1996 18 203-210.
35. Mariotti S, Caturegli P, Barbesino G, Marino M, Del Prete GF, Chiovato L, Tonacchera M, De Carli M & Pinchera A. Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases. Clinical Endocrinology 1992 37 415-422.
36. Stein-Streilein J, Zakarija M, Papic M & McKenzie JM. Hyperthyroxinemic mice have reduced natural killer cell activity, Evidence for a defective trigger mechanism. Journal of Immunology 1987 139 2502-2507.
37. Corrales JJ, Orfao A, Miralles JM & San Miguel J. The relationship between hyperthyroidism and the distribution of peripheral blood T, NK and B-lymphocytes in multinodular goiter. Hormone and Metabolic Research 1994 26 104-108.
38. Tofani A, Sciuto R, Cioffi RP, Pasqualoni R, Rea S, Festa A, Gandolfo GM, Arista MC & Maini CL. Radioiodine-induced changes in lymphocyte subsets in patients with differentiated thyroid carcinoma. European Journal of Nuclear Medicine 1999 26 824-829.
39. Molto L, Carballido J, Manzano L, Martinez-Martin B, Esquivel F, Chafer J, Olivier C & Alvarez-Mon M. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2. Journal of Immunotherapy 1999 22 260-267.